Wetzel Investment Advisors Inc. Takes Position in Pfizer Inc. (NYSE:PFE)

Wetzel Investment Advisors Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,706 shares of the biopharmaceutical company’s stock, valued at approximately $308,000.

Other large investors have also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. grew its position in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after acquiring an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC bought a new position in Pfizer in the 4th quarter valued at $255,000. Brookstone Capital Management grew its position in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after acquiring an additional 212,369 shares during the last quarter. ETF Store Inc. grew its position in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 727 shares during the last quarter. Finally, KLCM Advisors Inc. grew its position in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.4 %

Pfizer stock traded up $0.60 during midday trading on Friday, reaching $25.99. The company’s stock had a trading volume of 38,347,117 shares, compared to its average volume of 42,429,016. The stock’s 50-day simple moving average is $27.11 and its 200-day simple moving average is $28.68. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The stock has a market capitalization of $147.17 billion, a P/E ratio of 72.19, a PEG ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s revenue was down 41.3% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.